AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32083500 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 38
Study 35395069 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily
Number of subjects: 19114
Study 35395069 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily (females subgroup)
Number of subjects: 19114
Study 35395069 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily (males subgroup)
Number of subjects: 19114
Study 35395069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study 33636417 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day fasting intervention
Number of subjects: 20
Study 32125421 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 ppm stevia beverage
Number of subjects: 20
Study 32125421 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 20
Study 32125421 — intervention group
Group type: COMPARATOR
Intervention: Caloric beverages (maltodextrin, glucose, sucrose)
Number of subjects: 20
Study 35788383 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic analyses in NCI grants
Number of subjects: 146
Study 32579397 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair
Number of subjects: 35
Study 32579397 — intervention group
Group type: COMPARATOR
Intervention: Open Latarjet procedure
Number of subjects: 35
Study 35394711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat graft with I-PRF
Number of subjects: 20
Study 35394711 — intervention group
Group type: COMPARATOR
Intervention: Fat graft only
Number of subjects: 20
Study 33428673 — intervention group
Group type: COMPARATOR
Intervention: Acoustic brain entrainment (ABE) using frequency-modified music (400 and 418 Hz) during driving for 20 minutes.
Number of subjects: 80
Study 33428673 — intervention group
Group type: COMPARATOR
Intervention: Acoustic brain entrainment (ABE) during driving for 20 minutes.
Number of subjects: 80
Study 616037810 — intervention group
Group type: EXPERIMENTAL
Intervention: Centurion Vision System
Number of subjects: 101
Study 616037810 — intervention group
Group type: COMPARATOR
Intervention: Infiniti Vision System
Number of subjects: 101
Study 34495754 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable sutures
Number of subjects: 61
Study 34495754 — intervention group
Group type: COMPARATOR
Intervention: Nonabsorbable sutures
Number of subjects: 61
Study 35644071 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (4 mg/24 h for approximately eight days)
Number of subjects: 28
Study 35644071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 32587298 — intervention group
Group type: EXPERIMENTAL
Intervention: DiMAL 0.1 mM
Number of subjects: 2
Study 32587298 — intervention group
Group type: EXPERIMENTAL
Intervention: DiMAL 0.6 mM
Number of subjects: 2
Study 32587298 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC
Number of subjects: 2
Study 32587298 — intervention group
Group type: EXPERIMENTAL
Intervention: DiMAL
Number of subjects: 2
Study 32587298 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 2
Study 34116204 — intervention group
Group type: EXPERIMENTAL
Intervention: EPCO patients (excluded from PIRATE trial)
Number of subjects: 405
Study 34116204 — intervention group
Group type: COMPARATOR
Intervention: PIRATE patients (included in the trial)
Number of subjects: 405
Study 34116204 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluded patients for non-medical reasons
Number of subjects: 405
Study 34116204 — intervention group
Group type: EXPERIMENTAL
Intervention: EPCO patients with different treatment durations
Number of subjects: 405
Study 33768537 — intervention group
Group type: EXPERIMENTAL
Intervention: JASPER intervention (Joint Attention, Symbolic Play, Engagement, and Regulation) delivered by educators in the community.
Number of subjects: 179
Study 33768537 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (treatment as usual).
Number of subjects: 179
Study 35422402 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated segmentation using 2D U-Net architecture on sagittal images
Number of subjects: 57
Study 35422402 — intervention group
Group type: COMPARATOR
Intervention: Manual digitization
Number of subjects: 57
Study 32673102 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Videogames Group (IVG) - Nintendo Wii Sports (tennis, golf, boxing, bowling), 14 sessions, 50 minutes each, mild to moderate intensity
Number of subjects: 39
Study 32673102 — intervention group
Group type: COMPARATOR
Intervention: Active Exercises Group (AEG) - Similar movements to IVG, 14 sessions, 50 minutes each, mild to moderate intensity
Number of subjects: 39
Study 35122297 — intervention group
Group type: EXPERIMENTAL
Intervention: Way Back Support Service (WBSS) - a non-clinical after-care program for 3 months following a hospital-treated suicide attempt.
Number of subjects: 2770
Study 34403293 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic feedback and discussion of patient-reported outcomes (PRO) during consultation
Number of subjects: 279
Study 34403293 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 279
Study 33305386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (online intervention for psychosis)
Number of subjects: 124
Study 33305386 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting period)
Number of subjects: 124
Study 34455630 — intervention group
Group type: EXPERIMENTAL
Intervention: Soaking for 3 minutes
Number of subjects: 65
Study 34455630 — intervention group
Group type: EXPERIMENTAL
Intervention: Soaking for 5 minutes
Number of subjects: 65
Study 34455630 — intervention group
Group type: EXPERIMENTAL
Intervention: Soaking for 10 minutes
Number of subjects: 65
Study 34455630 — intervention group
Group type: EXPERIMENTAL
Intervention: Soaking for 15 minutes
Number of subjects: 65
Study 34455630 — intervention group
Group type: EXPERIMENTAL
Intervention: Soaking for 20 minutes
Number of subjects: 65
Study 34049532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogniaction project intervention
Number of subjects: 0
Study 34049532 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32419281 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones (100 mg daily for 8 weeks)
Number of subjects: 40
Study 32419281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32758312 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (PE-A)
Number of subjects: 63
Study 32758312 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling (SC)
Number of subjects: 63
Study 35315908 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Anesthesia
Number of subjects: 0
Study 35315908 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia
Number of subjects: 0
Study 35315908 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Transfusion
Number of subjects: 0
Study 35315908 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, Preoperative Delirium, Preexisting Dementia, Center
Number of subjects: 0
Study 32340841 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 36
Study 32340841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 32936442 — intervention group
Group type: COMPARATOR
Intervention: Basal diet
Number of subjects: 30
Study 32936442 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 2% more soluble fibers (SF)
Number of subjects: 30
Study 32936442 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 4% more soluble fibers (SF)
Number of subjects: 30
Study 32936442 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 2% more insoluble fibers (ISF)
Number of subjects: 30
Study 32936442 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 4% more insoluble fibers (ISF)
Number of subjects: 30
Study 32936442 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight gain (BWG)
Number of subjects: 30
Study 32936442 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose concentration
Number of subjects: 30
Study 32936442 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cholesterol concentration
Number of subjects: 30
Study 32936442 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration of HDL and LDL
Number of subjects: 30
Study 32936442 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood concentration of triglyceride
Number of subjects: 30
Study 32936442 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood concentration of VLDL
Number of subjects: 30
Study 32936442 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma enzyme activity of ALT
Number of subjects: 30
Study 33394814 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair analysis
Number of subjects: 69
Study 33394814 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported drug use by questionnaires
Number of subjects: 69
Study 32339768 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Reduction through Family Therapy (RRFT)
Number of subjects: 0
Study 32339768 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36151949 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial washing using a 4.0-mm thin bronchoscope under virtual bronchoscopic navigation guidance
Number of subjects: 85
Study 36151949 — intervention group
Group type: COMPARATOR
Intervention: Bronchial washing using a 5.9-mm conventional bronchoscope
Number of subjects: 85
Study 33976537 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lidocaine (Group HL: 1.5 mg/kg bolus followed by an infusion at 2.0 mg/kg/hour)
Number of subjects: 135
Study 33976537 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lidocaine (Group LL: 1.5 mg/kg bolus followed by an infusion at 1.0 mg/kg/hour)
Number of subjects: 135
Study 33976537 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C: received a volume-matched normal saline at the same rate)
Number of subjects: 135
Study 33976537 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lidocaine (Group HL)
Number of subjects: 135
Study 33976537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine groups (both HL and LL)
Number of subjects: 135
Study 33976537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine administration
Number of subjects: 135
Study 32887655 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder‐driven Community Diffusion Survey (SDCD)
Number of subjects: 10
Study 35234723 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Passive Motion (CPM)
Number of subjects: 51
Study 35234723 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 51
Study 34260478 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, vegan diet including ½ cup (86 g) of cooked soybeans daily for 12 weeks
Number of subjects: 38
Study 34260478 — intervention group
Group type: COMPARATOR
Intervention: No diet changes for 12 weeks
Number of subjects: 38
Study 32077907 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial observation with aflibercept only if visual acuity (VA) worsened
Number of subjects: 236
Study 32077907 — intervention group
Group type: COMPARATOR
Intervention: Initial observation
Number of subjects: 236
Study 32077907 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline central subfield thickness at least 300 μm
Number of subjects: 236
Study 32077907 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately severe nonproliferative diabetic retinopathy (ETDRS level 47 and above)
Number of subjects: 236
Study 32077907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonstudy eye received DME treatment within 4 months of randomization
Number of subjects: 236
Study 35794673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen 1 g 4 times a day
Number of subjects: 112
Study 35794673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 32402480 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg i.v. haloperidol
Number of subjects: 118
Study 32402480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 36476361 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-endoscopic disc decompression
Number of subjects: 0
Study 36476361 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical disc decompression
Number of subjects: 0
Study 33395437 — intervention group
Group type: EXPERIMENTAL
Intervention: COTiD-UK (Community Occupational Therapy for people with dementia)
Number of subjects: 468
Study 33395437 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 468
Study 32252062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg) infusion
Number of subjects: 34
Study 35471655 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (20 l · min‐1 with 40% oxygen concentration) with head-of-bed elevation
Number of subjects: 23
Study 35471655 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (20 l · min‐1 with 40% oxygen concentration) without head-of-bed elevation
Number of subjects: 23
Study 35471655 — intervention group
Group type: COMPARATOR
Intervention: Head-of-bed elevation alone (control)
Number of subjects: 23
Study 35471655 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula with head-of-bed elevation compared to high-flow nasal cannula alone
Number of subjects: 23
Study 35471655 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (alone or in combination with head-of-bed elevation)
Number of subjects: 23
Study 32829585 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplexed real-time PCR approach using LNA-modified primers
Number of subjects: 753
Study 32127335 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2000 mg docosahexaenoic acid + 400 mg eicosapentaenoic acid/day)
Number of subjects: 152
Study 32127335 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (160 mg/day)
Number of subjects: 152
Study 32127335 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fish oil and curcumin
Number of subjects: 152
Study 32127335 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 152
Study 35325628 — intervention group
Group type: EXPERIMENTAL
Intervention: REACT programme (12-month community-based group physical activity and behaviour maintenance intervention)
Number of subjects: 0
Study 35325628 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 33330909 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) catheter ablation
Number of subjects: 255
Study 33330909 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug (AAD) therapy
Number of subjects: 255
Study 32600489 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based peer volunteer support intervention
Number of subjects: 574
Study 32600489 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteers' experiences providing support
Number of subjects: 574
Study 34131051 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial approach (TRA)
Number of subjects: 92
Study 34689732 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children - for Teachers (ICC-T) intervention
Number of subjects: 4320
Study 34689732 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 4320
Study 33829299 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (alloSCT)
Number of subjects: 39
Study 33079154 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of praliciguat daily for 12 weeks (n=91)
Number of subjects: 196
Study 33079154 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks (n=90)
Number of subjects: 196
Study 34116619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate closure (CAA)
Number of subjects: 398
Study 34116619 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 398
Study 32131876 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led health coaching program
Number of subjects: 140
Study 32131876 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 140
Study 35795714 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (400 mg/kg daily for five consecutive days starting at 4-6 weeks of gestation)
Number of subjects: 102
Study 35795714 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (400 mg/kg daily for five consecutive days starting at 4-5 weeks of gestation)
Number of subjects: 102
Study 35795714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 35795714 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 102
Study 34270930 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of Lactobacillus casei Zhang (L. casei Zhang)
Number of subjects: 0
Study 34270930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33196565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral mydriatic-anesthetic (Mydrane/Fydrane)
Number of subjects: 50
Study 33196565 — intervention group
Group type: COMPARATOR
Intervention: Topical eyedrops only (Control)
Number of subjects: 50
Study 32610451 — intervention group
Group type: EXPERIMENTAL
Intervention: Untargeted metabolomics approach with IMS-HRMS
Number of subjects: 0
Study 32610451 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33634869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 100 mg (Pem100)
Number of subjects: 114
Study 33634869 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab 200 mg (Pem200)
Number of subjects: 114
Study 33634869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 100 mg (Pem100) with chemotherapy
Number of subjects: 114
Study 33634869 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab 200 mg (Pem200) with chemotherapy
Number of subjects: 114
Study 33634869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis for Pembrolizumab 100 mg (Pem100)
Number of subjects: 114
Study 36167573 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral co‐trimoxazole 960 mg once daily for 18 months
Number of subjects: 432
Study 36167573 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 18 months
Number of subjects: 432
Study 33085707 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher reward size
Number of subjects: 149
Study 33085707 — intervention group
Group type: COMPARATOR
Intervention: Lower reward size
Number of subjects: 149
Study 34915468 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable breath CH4
Number of subjects: 1126
Study 34915468 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in breath CH4 over time
Number of subjects: 1126
Study 34915468 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger drop in CH4
Number of subjects: 1126
Study 34776207 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability exercises
Number of subjects: 39
Study 34776207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory-motor exercises
Number of subjects: 39
Study 34776207 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study 35633124 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC (rivaroxaban, apixaban)
Number of subjects: 200
Study 35633124 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (low molecular weight heparin and vitamin K antagonists)
Number of subjects: 200
Study 32393412 — intervention group
Group type: EXPERIMENTAL
Intervention: OLZ/SAM
Number of subjects: 281
Study 33472925 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioned autologous MSC injections
Number of subjects: 54
Study 33472925 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone (control group)
Number of subjects: 54
Study 33324969 — intervention group
Group type: EXPERIMENTAL
Intervention: Nested trial designs
Number of subjects: 0
Study 33324969 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnested trial designs
Number of subjects: 0
Study 33324969 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite data-set designs
Number of subjects: 0
Study 32828488 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptides (14 trials; n=2207)
Number of subjects: 56047
Study 32828488 — intervention group
Group type: EXPERIMENTAL
Intervention: Inodilators (13 trials; n=2941)
Number of subjects: 56047
Study 32828488 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressors (4 trials; n=1047)
Number of subjects: 56047
Study 32828488 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide donors, alpha‐2‐agonists, and calcium channel blockers
Number of subjects: 56047
Study 36357795 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide (3 doses of 50 µg/day)
Number of subjects: 46
Study 36357795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 34491267 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake DBS (local anesthesia)
Number of subjects: 110
Study 34491267 — intervention group
Group type: COMPARATOR
Intervention: Asleep DBS (general anesthesia)
Number of subjects: 110
Study 35817419 — intervention group
Group type: EXPERIMENTAL
Intervention: CONVEX (n=15)
Number of subjects: 47
Study 35817419 — intervention group
Group type: EXPERIMENTAL
Intervention: CONCAVE (n=16)
Number of subjects: 47
Study 35817419 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (n=16)
Number of subjects: 47
Study 35817419 — intervention group
Group type: EXPERIMENTAL
Intervention: CONVEX
Number of subjects: 47
Study 35817419 — intervention group
Group type: EXPERIMENTAL
Intervention: CONCAVE
Number of subjects: 47
Study 35817419 — intervention group
Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 47
Study 33807731 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-hydroxybutyrate salts
Number of subjects: 22
Study 33807731 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo
Number of subjects: 22
Study 32921989 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine 2 μg kg−1 (Group D)
Number of subjects: 66
Study 32921989 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 μg kg−1 and ketamine 2 mg kg−1 (Group DK)
Number of subjects: 66